Bepotastine besilate for the treatment of pruritus

Bibliography

• Moses S. Pruritus. Am Fam Physician 2003;68(6):1135-42
   PubMed Web of Science ®Google Scholar
• Tanizaki H, Ikoma A, Fukuoka M, et al. Effects of bepotastine and fexofenadine on histamine-induced flare, wheal and itch. Int Arch Allergy Immunol 2012;158(2):191-5
   PubMed Web of Science ®Google Scholar
• Shim WS, Tak MH, Lee MH, et al. TRPV1 mediates histamine-induced itching via the activation of phospholipase A2 and 12-lipoxygenase. J Neurosci 2007;27(9):2331-7
   PubMed Web of Science ®Google Scholar
• Kim BM, Lee SH, Shim WS, Oh U. Histamine-induced Ca(2+) influx via the PLA(2)/lipoxygenase/TRPV1 pathway in rat sensory neurons. Neurosci Lett 2004;361(1-3):159-62
   PubMed Web of Science ®Google Scholar
• Kitaba S, Murota H, Yahata Y, et al. Novel functional aspect of antihistamines: the impact of bepotastine besilate on substance p-induced events. J Allergy 2009;2009:853687
   Google Scholar
• Williams JI, Gow JA, Klier SM, et al. Non-clinical pharmacology, pharmacokinetics, and safety findings for the antihistamine bepotastine besilate. Curr Med Res Opin 2010;26(10):2329-38
   PubMed Web of Science ®Google Scholar
• Meier EJ, Torkildsen GL, Gow JA, et al. Integrated phase III trials of bepotastine besilate ophthalmic solution 1.5% for ocular itching associated with allergic conjunctivitis. Allergy Asthma Proc 2012;33(3):265-74
   PubMed Web of Science ®Google Scholar
• Bielory L, Friedlaender MH. Allergic conjunctivitis. Immunol Allergy Clin North Am 2008;28(1):43-58; vi
   PubMed Web of Science ®Google Scholar
• Wingard JB, Mah FS. Critical appraisal of bepotastine in the treatment of ocular itching associated with allergic conjunctivitis. Clin Ophthalmol 2011;5:201-7
   PubMedGoogle Scholar
• Bielory L. Allergic conjunctivitis: the evolution of therapeutic options. Allergy Asthma Proc 2012;33(2):129-39
   PubMed Web of Science ®Google Scholar
• McCabe CF, McCabe SE. Comparative efficacy of bepotastine besilate 1.5% ophthalmic solution versus olopatadine hydrochloride 0.2% ophthalmic solution evaluated by patient preference. Clin Ophthalmol 2012;6:1731-8
   PubMedGoogle Scholar
• Abelson MB, Torkildsen GL, Williams JI, et al. Time to onset and duration of action of the antihistamine bepotastine besilate ophthalmic solutions 1.0% and 1.5% in allergic conjunctivitis: a phase III, single-center, prospective, randomized, double-masked, placebo-controlled, conjunctival allergen challenge assessment in adults and children. Clin Ther 2009;31(9):1908-21
   PubMed Web of Science ®Google Scholar
• Singh K, Axelrod S, Bielory L. The epidemiology of ocular and nasal allergy in the United States, 1988-1994. J Allergy Clin Immunol 2010;126(4):778-83; e776
   PubMed Web of Science ®Google Scholar
• Galor A, Feuer W, Lee DJ, et al. Prevalence and risk factors of dry eye syndrome in a United States veterans affairs population. Am J Ophthalmol 2011;152(3):377-84; e372
   PubMed Web of Science ®Google Scholar
• Yu J, Asche CV, Fairchild CJ. The economic burden of dry eye disease in the United States: a decision tree analysis. Cornea 2011;30(4):379-87
   PubMed Web of Science ®Google Scholar
• Pflugfelder SC. Prevalence, burden, and pharmacoeconomics of dry eye disease. Am J Manag Care 2008;14(3 Suppl):S102-6
   PubMedGoogle Scholar
• Smith AF, Waycaster C. Estimate of the direct and indirect annual cost of bacterial conjunctivitis in the United States. BMC Ophthalmol 2009;9:13
   PubMed Web of Science ®Google Scholar
• Bielory L. Update on ocular allergy treatment. Expert Opin Pharmacother 2002;3(5):541-53
   PubMedGoogle Scholar
• Yato N, Murata T, Saito N, et al. Anti-allergic activity of betotastine besilate (TAU-284), a new anti-allergic drug. Nihon Yakurigaku Zasshi 1997;110(1):19-29
   PubMedGoogle Scholar
• Kadosaka T, Shiraishi K, Mizuuchi H, et al. Phase I study of TAU-284: repeated oral administration in healthy male volunteers [in Japanese]. Rinsho Iyaku 1997;13(5):1155-68
   Google Scholar
• Andoh T, Kuraishi Y. Suppression by bepotastine besilate of substance P-induced itch-associated responses through the inhibition of the leukotriene B4 action in mice. Eur J Pharmacol 2006;547(1-3):59-64
   PubMed Web of Science ®Google Scholar
• Tanizaki H, Kambe N, Nakamura Y, et al. Oral administration of bepotastine besilate suppressed scratching behavior of atopic dermatitis model NC/Nga mice. Int Arch Allergy Immunol 2008;145(4):277-82
   PubMed Web of Science ®Google Scholar
• Kaminuma O, Ogawa K, Kikkawa H, et al. A novel anti-allergic drug, betotastine besilate, suppresses interleukin-5 production by human peripheral blood mononuclear cells. Biol Pharm Bull 1998;21(4):411-13
   PubMed Web of Science ®Google Scholar
• Sakai A, Kikuchi M, Yato N, et al. Inhibitory effect of betotastine besilate on antigen-induced airway eosinophil infiltration and peripheral blood eosinophilia in mice. Arzneimittelforschung 1997;47(8):954-8
   PubMed Web of Science ®Google Scholar
• Kida T, Fujii A, Sakai O, et al. Bepotastine besilate, a highly selective histamine H1 receptor antagonist, suppresses vascular hyperpermeability and eosinophil recruitment in in vitro and in vivo experimental allergic conjunctivitis models. Exp Eye Res 2010;91:85-91
   PubMed Web of Science ®Google Scholar
• Kato M, Nishida A, Aga Y, et al. Pharmacokinetic and pharmacodynamic evaluation of central effect of the novel antiallergic agent betotastine besilate. Arzneimittelforschung 1997;47(10):1116-24
   PubMed Web of Science ®Google Scholar
• Yokota H, Mizuuchi H, Maki T, et al. Phase I study of TAU-284: single oral administration in healthy male volunteers [in Japanese]. Rinsho Iyaku 1997;13(5):1155-68
   Google Scholar
• Lyseng-Williamson KA. Oral bepotastine: in allergic disorders. Drugs 2010;70(12):1579-91
   PubMed Web of Science ®Google Scholar
• Bepotastine [Package Insert] Labeling
   Google Scholar
• Talion® tablets (bepotastine besilate): product information. Tanabe Seiyaku Co. Ltd; Osaka: 2006
   Google Scholar
• Tashiro M, Duan X, Kato M, et al. Brain histamine H1 receptor occupancy of orally administered antihistamines, bepotastine and diphenhydramine, measured by PET with 11C-doxepin. Br J Clin Pharmacol 2008;65(6):811-21
   PubMed Web of Science ®Google Scholar
• Bepotastine. Lexi-Comp, Inc. (Lexi-Drugs™). 2013
   Google Scholar
• CDER Application Number 22-228 Summary Review
   Google Scholar
• Macejko TT, Bergmann MT, Williams JI, et al. Multicenter clinical evaluation of bepotastine besilate ophthalmic solutions 1.0% and 1.5% to treat allergic conjunctivitis. Am J Ophthalmol 2010;150(1):122-7; e125
   PubMed Web of Science ®Google Scholar
• Kumagai Y, Uchiumi M, Murasaki M, et al. Pharmacokinetics study of TAU-284 in elderly volunteers [in Japanese]. Rinsho Iyaku 1997;13(5):1169-85
   Google Scholar
• Kazutake K, Masaki S, Satomi T, et al. Clinical pharmacokinetic study of Talion® tablet (bepotastine besilate) in nephropathic patients (post-marketing clinical trial) [in Japanese]. Rinsho Iyaku 2003;19(6):1401-12
   Google Scholar
• Williams JI, Kennedy KS, Gow JA, et al. Prolonged effectiveness of bepotastine besilate ophthalmic solution for the treatment of ocular symptoms of allergic conjunctivitis. J Ocul Pharmacol Ther 2011;27(4):385-93
   PubMed Web of Science ®Google Scholar
• Kawakami T, Kimura S, Haga T, et al. Health-related quality of life assessed by the effect of bepotastine besilate in patients with pruritus: importance of emotions score in atopic dermatitis. J Dermatol 2012;39(6):527-30
   PubMed Web of Science ®Google Scholar
• Nakahara T, Urabe K, Moroi Y, et al. Bepotastine besilate rapidly inhibits mite-antigen induced immediate reactions in atopic dermatitis. J Dermatol Sci 2003;32(3):237-8
   PubMed Web of Science ®Google Scholar
• Takasaki K, Enatsu K, Kumagami H, Takahashi H. Concentrations of H1-receptor antagonist in the human nasal mucosa. Int J Otolaryngol 2009;2009:495186; 1-4
   PubMedGoogle Scholar
• SD. W. Clinical review of bepotastine besilate ophthalmic solution 1.5%. FDA 2009
   Google Scholar
• Hussar DA, Abbas CA. New drugs: asenapine, iloperidone, and bepotastine besilate. J Am Pharm Assoc (Wash DC) 2010;50(1):107-10
   Google Scholar
• Bepotastine besilate. Office of Clinical Pharmacology Review: FDA. 2009
   Google Scholar
• Torkildsen GL, Williams JI, Gow JA, et al. Bepotastine besilate ophthalmic solution for the relief of nonocular symptoms provoked by conjunctival allergen challenge. Ann Allergy Asthma Immunol 2010;105(1):57-64
   PubMed Web of Science ®Google Scholar
• Bergman et al. Clinical pharmacology review of bepotastine besilate ophthalmic solution 1.5%. FDA 2009
   Google Scholar
• Kawashima K, Sakai M, Takatsuka S, et al. Clinical pharmacokinetic study of Talion® tablet (bepotastine besilate) in nephropathic patients (post-marketing clinical trial) [in Japanese]. J Clin Ther Med 2003;19(6):1401-12
   Google Scholar
• Hishinuma S, Sato Y, Kobayashi Y, et al. Intact cell binding for in vitro prediction of sedative and non-sedative histamine H1-receptor antagonists based on receptor internalization. J Pharmacol Sci 2008;107(1):66-79
   PubMed Web of Science ®Google Scholar
• Ueno M, Inagaki N, Nagai H, Koda A. Antiallergic action of bepotastine besilate (Tau-284) in animal models: a comparison with ketotifen. Pharmacology 1998;57(4):206-14
   PubMed Web of Science ®Google Scholar
• Sharif NA, et al. J Ocul Pharmacol 1994;10(4):653-63
   PubMedGoogle Scholar
• Kubo N, Shirakawa O, Kuno T, Tanaka C. Antimuscarinic effects of antihistamines: quantitative evaluation by receptor-binding assay. Jpn J Pharmacol 1987;43(3):277-82
   PubMedGoogle Scholar
• Bielory L, Lien KW, Bigelsen S. Efficacy and tolerability of newer antihistamines in the treatment of allergic conjunctivitis. Drugs 2005;65(2):215-28
   PubMed Web of Science ®Google Scholar
• Wade L, Bielory L, Rudner S. Ophthalmic antihistamines and H1-H4 receptors. Curr Opin Allergy Clin Immunol 2012;12(5):510-16
   PubMed Web of Science ®Google Scholar